ReNAgade Therapeutics, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Antisense, Oligonucleotides
    • Drug Discovery Technologies
      • Genomics-Proteomics
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
See more in Biomedtracker

Latest on ReNAgade Therapeutics, Inc.

Scrip

Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Pink Sheet

BIO Notebook Day 3: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

 
• By Pink Sheet Team

Venture Capital Musical Chairs May Leave Some Without A Seat Venture capital investment in biotechnology companies has declined significantly in 2023 as VC investors reserve cash for companies they ba

Scrip

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle

 
• By Mandy Jackson

The volume of $100m-plus venture capital mega-rounds continues to build throughout 2023 after a slow start, but a wider look at the biopharmaceutical VC landscape illustrates the valley of death that

Scrip

BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird

 
• By Scrip Team

Venture Capital Musical Chairs May Leave Some Without A Seat Venture capital investment in biotechnology companies has declined significantly in 2023 as VC investors reserve cash for companies they ba